URGN Stock Overview
A biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
UroGen Pharma Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$13.08 |
52 Week High | US$24.13 |
52 Week Low | US$8.69 |
Beta | 1.09 |
1 Month Change | -8.53% |
3 Month Change | -27.53% |
1 Year Change | 24.69% |
3 Year Change | -29.37% |
5 Year Change | -63.03% |
Change since IPO | -6.44% |
Recent News & Updates
Recent updates
UroGen Pharma Ltd. (NASDAQ:URGN) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough
Apr 09UroGen: All Eyes On UGN-102
Mar 18UroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Annual Results And Analysts Are Updating Their Estimates
Mar 17UroGen Pharma Ltd. (NASDAQ:URGN) Looks Inexpensive But Perhaps Not Attractive Enough
Jan 18UroGen gets FDA nod for extending duration of Jelmyto admixture
Sep 28UroGen Pharma (NASDAQ:URGN) Is In A Good Position To Deliver On Growth Plans
Mar 09We're Not Very Worried About UroGen Pharma's (NASDAQ:URGN) Cash Burn Rate
Nov 04Shareholder Returns
URGN | US Biotechs | US Market | |
---|---|---|---|
7D | -3.9% | 2.4% | -0.6% |
1Y | 24.7% | 6.7% | 21.7% |
Return vs Industry: URGN exceeded the US Biotechs industry which returned 6.3% over the past year.
Return vs Market: URGN exceeded the US Market which returned 22.4% over the past year.
Price Volatility
URGN volatility | |
---|---|
URGN Average Weekly Movement | 9.0% |
Biotechs Industry Average Movement | 10.6% |
Market Average Movement | 5.8% |
10% most volatile stocks in US Market | 15.6% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: URGN's share price has been volatile over the past 3 months.
Volatility Over Time: URGN's weekly volatility has decreased from 17% to 9% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2004 | 204 | Liz Barrett | www.urogen.com |
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company’s lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC).
UroGen Pharma Ltd. Fundamentals Summary
URGN fundamental statistics | |
---|---|
Market cap | US$474.39m |
Earnings (TTM) | -US$104.32m |
Revenue (TTM) | US$84.30m |
5.6x
P/S Ratio-4.5x
P/E RatioIs URGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
URGN income statement (TTM) | |
---|---|
Revenue | US$84.30m |
Cost of Revenue | US$8.82m |
Gross Profit | US$75.48m |
Other Expenses | US$179.80m |
Earnings | -US$104.32m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -2.89 |
Gross Margin | 89.53% |
Net Profit Margin | -123.74% |
Debt/Equity Ratio | -243.2% |
How did URGN perform over the long term?
See historical performance and comparison